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Background: NIPBL, the sister chromatid cohesion 2 (SCC2) human homolog, is a cohesin loading factor which is
essential for deposition of cohesin onto the sister chromatid. Recent studies have shown that NIPBL contribute to
sister chromatid cohesion and plays a critical role in development, DNA repair, and gene regulation. In this study,
we measured the expression of NIPBL in clinical non-small cell lung cancer specimens, and determined its effects
on cellular processes and chemosensitivity in vitro.
Methods: NIPBL immunohistochemistry was performed on 123 lung adenocarcinoma samples. Through knockdown
of NIPBL protein expression, non-small cell lung cancer cell lines were used to test the potential involvement of NIPBL
silencing on cell proliferation, migration, invasion, and apoptosis. Chemosensitivity was assessed with clonogenic assays,
and chromatin immunoprecipitation assays were performed to analyze the relationship between NIPBL and signal
transducers and activators of transcription 3 (STAT3).
Results: Immunohistochemical analysis showed that high expression of NIPBL was strongly correlated with poor
prognosis, tumor differentiation, and lymph node metastasis. Survival analysis further indicated that NIPBL expression
was a potential prognostic factor for non-small cell lung cancer. Knockdown of NIPBL in non-small cell lung cancer cell
lines significantly reduced cellular proliferation, migration, and invasion, and enhanced cellular apoptosis and sensitivity
to cisplatin, paclitaxel, and gemcitabine hydrochloride. NIPBL bound to the promoter region of the STAT3 gene, directly
regulating the expression of STAT3.
Conclusions: These data suggested that NIPBL played a significant role in lung carcinogenesis. NIPBL expression
conferred poor prognosis and resistance to chemotherapy in non-small cell lung cancer, suggesting that NIPBL may be
a novel therapeutic target.
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In eukaryotic cells, a group of conserved proteins termed
cohesins form a complex that holds the two sister chro-
matids together during DNA replication in S phase, until
their separation at the onset of anaphase. This biological
process is termed sister chromatid cohesion. The core* Correspondence: maowm1218@163.com
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unless otherwise stated.cohesin complex consists of four proteins, SCC1 (also
known as RAD21), SCC3 (STAG1, STAG2), SMC1A,
and SMC3. These proteins form a ringlike structure
which can encircle the DNA [1]. A number of regulatory
factors have been found to play roles in cohesin func-
tion, such as the SCC2/SCC4 loading complex, the cohe-
sin maintenance WAPL/PDS5 complex proteins, and
protein acetyltransferase ESCO2 [2,3].
Cohesin loading factor SCC2 is evolutionarily well con-
served [4]. NIPBL is a human homolog of SCC2. NIPBL/
Nipped-B protein is found in the nuclei of all eukaryotic
cells, where it interacts with the cohesin complex thatis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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addition to its role in sister chromatid cohesion, NIPBL/
Nipped-B/Nipbl also functions in the regulation of gene
expression [5,6]. In Drosophila, for example, it was
shown that Nipped-B was required for long range pro-
moter enhancer activation of the Cut and Utrabithorax
homeobox genes, which control multiple aspects of devel-
opment [7]. Nipped-B and cohesin colocalized to sites
enriched within the promoter regions of the dysregulated
genes [8]. Mutations in NIPBL have been identified in ap-
proximately 60% of individuals with Cornelia de Lange
syndrome (CdLS) [9,10]. This dominant, genetically het-
erogeneous developmental disorder is characterized by
craniofacial anomalies, growth retardation, upper limb de-
fects, intellectual disability, and gastrointestinal and geni-
tourinary developmental abnormalities. Observations in
CdLS patients and mouse models showed that heterozy-
gous NIPBL mutations produced only a 25 ~ 30% drop in
transcript levels [11-13]. Gene expression profiling dem-
onstrated that small changes in NIPBL/Nipbl levels led to
significant transcriptional dysregulation of many genes in
Nipbl+/− mice, and in NIPBL mutant human cells, the ex-
pression levels of NIPBL/Nipbl correlated with the pheno-
typic severity of the CdLS disorder [13,14]. These results
implied that extreme sensitivity to development correlated
with small changes in NIPBL activity. Most recently, a
study using different human cell lines and lymphoblastoid
cell lines derived from CdLS patients demonstrated that
high affinity NIPBL binding sites almost exclusively local-
ized to the promoters of active genes, in a cohesin-
independent manner [15]. Further studies found that
NIPBL could recruit histone deacetylases, and repress pro-
moter activity [16]. These observations suggested that
NIPBL expression levels were critical for cells. NIPBL may
act as a transcription factor and may have an upstream
role in gene regulation in multiple ways through interac-
tions with the transcriptional machinery.
It was found that a number of NIPBL binding genes
were important during development and were known to
be dysregulated in cancer. For example, Nipped-B/Nipbl
could positively regulate the transcription of Myc, Oct4,
and Nanog genes in Drosophila and mouse embryonic
stem cells [17,18]. These genes are crucial for cell prolif-
eration and maintenance of pluripotency. In addition,
data from the Somatic Mutation in Cancer (COSMIC)
database suggested that rare NIPBL mutations were
identified in lung carcinoma, breast carcinoma, and
colorectal tumors [19]. In a genome-wide functional
screen, NIPBL was identified as one of 11 signature
genes whose silencing caused tamoxifen resistance [20].
Although these results and analyses implied that abnor-
mal NIPBL may be a significant feature or might con-
tribute to carcinogenesis, there are no data currently
available from clinical cancer samples.Lung cancer is one of the most common malignancies
worldwide. In the past decade, lung adenocarcinoma, a
subtype of non-small cell lung cancer (NSCLC), has be-
come the most common histological type among all lung
cancers diagnosed. Despite the common occurrence, un-
derstanding of the NSCLC genetic molecular back-
ground and underlying molecular mechanism leading to
its growth and progression remain incomplete. Here, we
evaluated the expression of NIPBL in clinical samples of
lung adenocarcinoma, and found that almost one-third
of the samples expressed high levels of NIPBL protein,
and high NIPBL expression was associated with poor
clinical outcome. Small interference RNA (siRNA) medi-
ated knockdown of NIPBL significantly impaired cellular
proliferation, migration, and invasion, and enhanced the
proapoptotic effects of chemotherapy on NSCLC cell
lines. These results provided the first evidence that ab-
normal NIPBL expression might either play a direct role




Lung adenocarcinoma specimens were obtained from pa-
tients who underwent pulmonary lobectomy at Zhejiang
Cancer Hospital from 2008 to 2009, and the study was
approved by the Ethic Committee of Zhejiang Cancer
Hospital and all patients gave informed consent. Patient
medical records were review to obtain tumor staging,
pathology, and survival information. Clinicopathological
classification and staging of these samples were based
on the World Health Organization histological classifi-
cation of tumors of the lung [21] and AJCC Cancer Sta-
ging Manual, 7th Edition(2010)_ lung cancer. Patient
median age was 57.03 years (range from 29 to 81 years).
Among 136 cases of lung adenocarcinoma that we ex-
amined, follow-up results were available on 123 cases.
Patient median follow-up was 50 months.
Immunohistochemistry and staining evaluation
Immunohistochemistry was performed on 4 μm sections
of paraffin-embedded tissue samples. Immunohistochemi-
cal staining was done using a SPlink Detection Kits (SP-
9000, ZSGB-BIO, China) according to the manufacture’s
protocol. Briefly, de-paraffinized and rehydrated tissue
sections were treated for antigen retrieval in 10 mM Tris–
HCl (pH 9.0) buffer containing 1 mM EDTA for 10 mi-
nutes at 100°C, then treated with 3% H2O2 for 10 minutes
to remove endogenous peroxides, Sections were incubated
with anti NIPBL antibody in rabbit (HPA040834, Sigma,
CA, USA) at 1:50 dilution, the signal was detected using
DAB (3,3′-diaminobenzidine) substrate. Immunohisto-
chemical evaluation was performed separately by two
pathologists knowing none about the patients’ clinical
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for the percentage of positive cells (quantity score:no
staining is scored as 0, 1–10% of cells stained scored as
1, 11–50% as 2, 51–80% as 3, and 81–100% as 4), and
intensity (staining intensity score: 0 = negative; 1 = weak;
2 = moderate, and 3 = strong). An overall protein ex-
pression score was calculated by multiplying the quan-
tity and staining intensity scores. The overall scores
could range from 0 to 12. For statistical analysis, an
overall staining score of ≥6 was considered to be high
expression of NIPBL protein, score of 0–5 was consid-
ered as low expression.
Cell lines and transfection
The human NSCLC cell lines H1299 and A549 were ob-
tained from the American Type Culture Collection
(ATCC, Rockville, MD, USA). H661, H1650 (lung adeno-
carcinoma cell line) were obtained From Cell Bank at the
Chinese Academy of Sciences (Shanghai, China). H1299,
H661 and H1650 cells were grown and maintained in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin. A549 cells
were cultured in F-12 Medium supplemented with 10%
fetal bovine serum.
Multiple siRNAs against human NIPBL and a scram-
ble control siRNA were constructed by Genepharma
(Genepharma, Shanghai, China). Two siRNAs (siNIPBL-
N2 and siNIPBL-N3) with the best silencing potential
(estimated using Western blot analysis, date not shown)
were chosen to silence NIPBL expression (The sequence
for NIPBL siRNA: siNIPBL-N2: 5′-GCUCGGAACAAA
GCAAUUA-3′, siNIPBL-N3:5′-GCGGCAAUGUAUGA
UAUAATT-3′. The sequence for control siRNA: siNIPBL-
NC: 5′-GGUUGCCGACUCGUUAAUATT-3′). Thansfec-
tion with siRNA was performed using Oligofectamine
(Invitrogen, Carlsbad, CA), all procedures were performed
according to manufacturer’s instructions.
Cell viability assay
The cell viability determined by MTT (Sigma-Aldrich,
St. Louis, MO) assay. 24 h after transfected with siRNA,
cells were trypsinized and plated in quintuplicates in 96-
well plates at the density of 1.5 × 103 per well (H1299) or
2.0 × 103 per well (H1650), respectively. The cells were
cultured for 4 h (day0, baseline) or 2–6 day. For colori-
metric analysis, the absorbance value (OD) at 490 nm
was measured with Multiskan Spectrum UV/visible
Mocroplate Reader (Thermo Labsystems, MA, USA).
The ratio of the absorbance relative to baseline was
calculated.
Clonogenic survival assay
Cell survival was measured based on colony formation.
H1299 and H1650 cells were transfected with siRNArespectively. 24 h after transfection, cells (500cells/well)
seeded in 12-well plates. After incubation for 14 days,
cells were fixed and stained with Crystal Violet to detect
colonies. Colonies containing at least 50 cells were
counted under microscope. The experiment was per-
formed in triplicate.
Two day after siRNA transfection, H1299 cells were
treated with various concentrations of cisplatin, Pacli-
taxel and Gemcitabine Hydrochlorid for 24 h, then cells
(500cells/well) were diluted in complete medium and
seeded in 12-well plates. Clonogenic survival assays was
performed as the same as above.
Cell migration and invasion assays
Cell migration assays were performed using transwell
from Costar with 6.5 mm diameter and 8.0 μm pore size,
added 1 × 104 cells in 300 μl serum-free media into
upper chamber of transwell, assessed the migration po-
tency after 24 h’s incubation. Count the number of cells
that migrated across the filter in 4 randomly high-power
fields per well. Three identical replicates preformed.
For cell invasion assays, 40 μl of the diluted matrigel
was added into the upper chamber of transwell, 5 × 104
cells in serum-free media were added to the upper
chamber, after incubation for 24 h, count the number of
migrated cells in 4 randomly high-power fields per well.
All experiments were performed in triplicate.
Flow cytometry analysis of apoptosis
48 h after transfection, H1299 cells were treated with
lower concentration of cisplatin (0.5 ng/ml), Gemcita-
bine hydrochlorid (0.02 ng/ml) or paclitaxel (0.2 ng/ml)
for 24 h. The Alexa Fluor 488 Annexin V/Dead Cell
Apoptosis Kit (Invitrogen, Oregon, USA) was used for
apoptosis analysis. Cells were collected and resuspended
in staining solution, the staining cells (1 × 105) were ana-
lysis with a flow cytometer (BD FACSCalibur, CA, USA).
Quantitative real time PCR analysis
Total RNA was extracted from cultured cells by using
Trizol reagent (Invitrogen, USA) according to the manu-
facturer’s instruction. cDNA synthesis using a Prime-
Script ™ RT Reagent Kit (Takara, Dalian, China). Real
time PCR was performed using Applied Biosystems 7500
real-time PCR System (ABI, CA, USA) to measure
mRNA levels of NIPBL, STAT3, Mcl-1, c-Myc, β-actin
was amplified as an internal control. The relative expres-
sions of above genes were determined from three inde-
pendent experiments. Primers used were listed in
Table 1.
Semi-quantitative Western blot analysis
Total protein was isolated from culture cells according
to a previous study [16]. Protein samples (50 μg) were
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PVDF membrane (Millipore, Bedford, MA). Primary
antibodies use anti-NIPBL antibody (1:1000, ABSea,
China), anti-C-Myc antibody, anti-STAT3 antibody,
anti-Mcl-1 antibody, anti-Bcl-2 antibody, anti-c-PARP
antibody, anti-c-Caspase-3 antibody and anti-Survivin
antibody (1:1000, Cell signaling, USA) respectively, Anti-
alpha Tubulin antibody (1:1000, Abcam, UK) as the
loading control. The relative level of protein expression
was quantified by image analyzing software Quantity
One (Version 4.5.2) (Bio-Rad, USA) and expressed as
means ± SD (n = 3).Chromatin immunoprecipitation (ChIP) assays
ChIP assays were preformed in H1299 cells according to
the manufacturer’s recommendation (EZ-ChIP™, Millipore,
17–371, USA). Proteins were cross-linked to chromatin
by adding formaldehyde to 1% final concentration. Chro-
matin was incubated with anti-NIPBL antibody (KT55,
ABSea, China) overnight at 4°C. DNA was purified using
spin columns. Primers used for STAT3 gene promoter
were follows: STAT3-p1 (148 bp, 5′-GGAGTACGGGGTT
AAATCCACTACC-3′ and 5′-GGACAACAAAAAGAAC
ATGGGTGAC-3′) and STAT3-p2 (116 bp, 5′-CTCCTA
GCTGCTCTCCTCAT-3′ and 5′-CACGCCGTCATGCA
TAATTC-3′), PCR products were subjected to electro-
phoresis using 1% agarose gel.Statistical analysis
Data were analyzed using the Statistical Package for the
Social Sciences (SPSS), Version 18 (SPSS, Chicago, IL,
USA). The Pearson’s chi-squared test was used to
analyze the relationship between NIPBL expression and
clinicopathologic characteristics. Kaplan-Meier plots
were constructed to present the survival outcomes and
were compared using a log-rank test. One-way ANOVA,
Student’s t-test, or chi-square tests were used to com-
pare differences between groups. A two-tailed P-valuetest was used in all analyses, and P < 0.05 in all cases was
considered statistically significant.
Results
NIPBL protein expression in lung adenocarcinoma tissues
NIPBL protein was localized mainly in the nucleus, and
no staining or minimal weak staining was present in the
cytoplasm in all cases. Expression of NIPBL in lung
adenocarcinoma ranged from weak to strong as deter-
mined by staining (Figure 1). According to our immuno-
histochemical staining evaluation, almost one-third of
the lung adenocarcinoma samples expressed high levels
of NIPBL protein (39/123 cases, 31.7%).
Association between NIPBL expression and
clinicopathological features in lung adenocarcinoma
As shown in Table 2, we found that NIPBL expression
was positively correlated with tumor differentiation
(P = 0.003) and lymph node metastasis (P = 0.029). No sig-
nificant associations were found between NIPBL expres-
sion and age, gender, or tumor, node, and metastasis
(TNM) stage (P > 0.05). High expression of NIPBL was as-
sociated with poor differentiation and a poor prognosis.
Using the Kaplan-Meier analysis method, we found that
there was a significant correlation between high NIPBL ex-
pression and shorter median overall survival (P = 0.003)
(Figure 2A). Moreover, the relapse free survival was signifi-
cantly higher in the low NIPBL level group than in the high
NIPBL level group (P = 0.006) (Figure 2B). In addition,
there was no correlation between NIPBL expression and
overall survival among patients who were not treated with
chemotherapy (P = 0.393) (Figure 2C), whereas among pa-
tients treated with chemotherapy, there was a significantly
shorter overall survival in patients whose tumors were
positive for NIPBL expression (P = 0.001) (Figure 2D).
NIPBL expression in NSCLC cell lines
Variations in NIPBL protein and mRNA expression
levels in four lung cancer cell lines H1299, A549, H661,
and H1650 were quantitated by using the quantitative
reverse-transcription polymerase chain reaction (qRT-
PCR) and western blot analysis. All four lung cancer
lines expressed the NIPBL protein, especially the H1299
and H1650 cell lines, in which NIPBL protein expression
was high (Figure 3A).
Knockdown of NIPBL inhibited proliferation, migration,
and invasion in H1299 and H1650 human NSCLC cell lines
We used two efficient siRNAs (siNIPBL-N2 and siNIPBL-
N3) to downregulate the NIPBL expression in H1299
and H1650 cell lines. Examination of NIPBL mRNA and
protein expression showed a statistical reduction in
both NSCLC cell lines transfected with siNIPBL-N2 and
siNIPBL-N3, compared to the control cells which were
Figure 1 Immunohistochemical staining of NIPBL in lung adenocarcinoma. The overall immunohistochemical staining scores could range from 0
to 12. An overall staining score of ≥6 was considered to be high expression of NIPBL protein, score of 0–5 was considered as low expression.
Low level of expression of NIPBL in lung adenocarcinoma sample: (A) Absence of nuclear NIPBL expression, overall staining score is 0, (B) overall
staining score is 1–2. High level expression of NIPBL in lung adenocarcinoma samples: (C) overall staining score is 6, (D) overall staining score is 8,
(E) and (F) overall staining score are 12. Original magnification: ×200.
Table 2 Association of NIPBL expression with clinical





Low, n (%) High, n (%)
Gender
Male 81 (65.9) 52 (61.9) 29 (74.4) 0.175
Female 42 (34.1) 32 (38.1) 10 (25.6)
Age (years)
<50 37 (30.1) 26 (31.0) 11 (28.2) 0.757
≥50 86 (69.9) 58 (69.0) 28 (71.8)
Tumor
differentiation
Well differentiated 34 (27.6) 29 (34.5) 5 (12.8) 0.003
Moderately
differentiated
47 (38.2) 34 (40.5) 13 (33.4)
Poorly differentiated 42 (34.2) 21 (25.0) 21 (53.8)
Lymph node
metastasis
Positive 81 (65.9) 50 (59.5) 31 (79.5) 0.029
Negative 42 (34.1) 34 (40.5) 8 (20.5)
Disease stage
I 36 (29.3) 26 (31.0) 10 (25.6) 0.794
II 53 (43.1) 36 (42.9) 17 (43.6)
III 34 (27.6) 22 (26.1) 12 (30.8)
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cell line, relative to the control siRNA-NC trahsfected
cells, the relative levels of NIPBL protein were 47 ± 6% for
siRNA-N2 transfected cells, 29 ± 4% for siRNA-N3 trans-
fected cells. In H1650 cell line, the relative levels of NIPBL
protein were 41 ± 4% for siRNA-N2 transfected cells,
43 ± 7% for siRNA-N3 transfected cells, relative to the
control siRNA-NC transfected cells (Figure 3B).
To test the potential involvement of NIPBL silencing
on cell growth and proliferation in NSCLC cells, we per-
formed MTT assays and clonogenic survival assays.
After 6 days in culture, H1299 cells transfected with
siNIPBL-N2 and siNIPBL-N3 showed 78.8% and 50.7%
survival, respectively, and H1650 NIPBL knockdown
cells showed 81.9% and 73.8% survival, compared to
control cells respectively, in a manner that directly cor-
related with the level of NIPBL expression (Figure 3C).
Consistently, we noted that NIPBL silenced cells exhib-
ited a significantly decreased ability to form colonies
compared to control cells at 14 days (Figure 3D).
To confirm the functional significance of our clinico-
pathological results that NIPBL expression was associ-
ated with tumor metastasis, we determined the effect of
NIPBL downregulation on cell migration and invasion in
H1299 and H1650 cells. As shown in Figure 3, treatment
with siNIPBL-N2 and siNIPBL-N3 significantly inhibited
both H1299 and H1650 cell migration across Transwell®
membranes in comparison with control cells (Figure 3E).
Similarly, at 24 h, silencing NIPBL expression in the
H1299 and H1650 cell lines also significantly decreased
Figure 2 Overall survival and relapse-free survival analysis in lung adenocarcinoma patients according to NIPBL expression. (A) Kaplan-Meier
analysis of tumor-specific overall survival by NIPBL expression in all lung adenocarcinoma patients (P =0.003) (n = 123). (B) Kaplan-Meier analysis
of relapse free survival by NIPBL expression (P =0.006) (n = 72). (C) Overall survival in patients without chemotherapy (P =0.393) (n = 48), (D) Overall
survival in patients treated with chemotherapy by NIPBL expression (P =0.001) (n = 75).
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pared with scrambled control siRNA treated cells (Figure 3F).
Knockdown of NIPBL enhanced sensitivity to
chemotherapy drugs in the H1299 cell line
To further test the functional significance of our cancer
therapy results that NIPBL expression affected sensitivityto chemotherapeutic drug responses, we investigated the
effect of downregulating endogenous NIPBL expression
on cell growth after exposure to chemotherapeutic drugs.
Clonogenic assays were performed on cells that were ini-
tially transfected with NIPBL siRNA, and subsequently ex-
posed to varying concentrations of cisplatin, paclitaxel,
and gemcitabine hydrochloride. After 14 days, compared
Figure 3 Knockdown of NIPBL inhibited proliferation, migration, and invasion in H1299 and H1650 human NSCLC cell lines. (A) RT-PCR analysis
of NIPBL mRNA level and Western blot analysis of NIPBL protein level in four human NSCLC cell lines. (B) Relative levels of NIPBL mRNA and
protein expression in H1299 and H1650 lung cancer cells transfected with siNIPBL-N2, −N3 or –NC (non-targeting scramble control siRNA).
Based on morphometric analysis of immunoblot data, in H1299 cell line, siRNA-N2 caused 47 ± 6% reduction, and siRNA-N3 caused 29 ± 4%
reduction in NIPBL protein level, in H1650 cell line, siRNA-N2 caused 41 ± 4% reduction, and siRNA-N3 caused 43 ± 7% reduction in
NIPBL protein level. (C) In vitro growth curves of H1299 and H1650 NSCLC cells which transfect with siNIPBL-N2,-N3, and –NC for 0–6
days. Cell viability was determined by MTT assay. For colorimetric analysis, the absorbance value (OD) at 490 nm was measured in the
cells which cultured for 4 h, as the baseline of day0. Data represented mean ± SD for three replicate experiments. (D) Clone formation
assays of NIPBL knockdown H1299 cells and H1650 cells. Cells were seeded at the cell numbers indicated, stained with crystal violet
after 2 weeks’ culture. Experiments were performed in triplicates. (E) The in vitro migratory ability of NIPBL downregulated H1299 and
H1650 cells was determined by in vitro migration. Cells migrated through the memberane were viewed at × 400 magnifications under
light microscope, counted in 4 independent visual fileds SEMper transwell membrane. Cell numbers were presented as values of
means ± SD of triplicate experiments. * P <0.05. (F) The in vitro invasive ability of NIPBL downregulated H1299 and H1650 cells was
further determined by same assay, as described in (E).
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showed significant reduction in the clonogenic survival
fraction when they were exposed to cisplatin (Figure 4A).Similarly, enhanced sensitivity was observed in the two
NIPBL knockdown cell cultures treated with paclitaxel
and gemcitabine hydrochloride (Figure 4B, C).
Figure 4 NIPBL knockdown enhanced cellular sensitivity to chemotherapy drugs, and increased chemotherapy drug-induced apoptosis in the
H1299 cell line. H1299 cells were transfected with siNIPBL or non-targeting scramble siRNA for 24 h, and then treated with different concentrations of
cisplatin, Gemcitabine hydrochlorid and paclitaxel for 24 h, seeded at the cell numbers indicated, cultured for 2 weeks. Clonogenic survival following
treatment with: (A) cisplatin; (B) paclitaxel; (C) Gemcitabine hydrochlorid. Data represented mean ± SD for three replicate experiments. (D) H1299 cells
were transfected with either siNIPBL or non-targeting scramble siRNA as indicated. After 48 h, cells were treated with lower concentration of cisplatin
(0.5 ng/ml), Gemcitabine hydrochlorid (0.02 ng/ml) and paclitaxel (0.2 ng/ml) for 24 h. The cells were collected and stained with Annexin-V-FITC and PI.
Shown were representative images of three independent experiments, values are expressed as a percentage of Annexin V positive versus total cells.
(E) Apoptosis index were presented as mean ± SD of triplicate experiments. * P <0.05.
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cell line
To examine whether increased sensitivity to chemother-
apeutic drugs was due to an increased apoptotic cell
death, the cellular apoptosis ratio of NIPBL knockdown
cells treated with lower concentrations of cisplatin, gem-
citabine hydrochloride, or paclitaxel was determined. As
shown in Figure 4D–E, compared with control cells, si-
lencing of NIPBL increased cell apoptosis significantly
after treatment with chemotherapeutic drugs (P < 0.05).
Knockdown of NIPBL inhibited expression of STAT3 and
STAT3 target genes, and NIPBL directly regulated the
expression of STAT3
Based on the above results, to further explore the mech-
anisms responsible for modulation of lung cancer cell
survival by NIPBL, we performed RNA-seq assays afterknockdown of NIPBL protein in H1299 cells (data not
shown). We observed that silencing of NIPBL was asso-
ciated with significantly decreased mRNA expression for
STAT3 and its target genes c-Myc, and Mcl-1. As illus-
trated in Figure 5A, qRT-PCR confirmed that the mRNA
levels of STAT3 (signal transducers and activators of
transcription 3) signaling pathway-related genes, such as
STAT3, Mcl-1, and c-Myc, were significantly decreased
when NIPBL was knocked down (P < 0.05). Importantly,
we also confirmed, by western blotting, that knockdown
of NIPBL significantly decreased the protein levels of
STAT3, Mcl-1, Bcl-2, and c-Myc (Figure 5B). Further-
more, NIPBL knockdown cells also exhibited markedly
increased activation of cleaved caspase-3 and cleaved
poly ADP-ribose polymerase (PARP), a substrate of
caspase-3. However, survivin, an inhibitor of cell death,
was not decreased (Figure 5B). Given that the STAT3-
Figure 5 Knockdown of NIPBL inhibited expression of STAT3-related gene, NIPBL directly regulate the expression of STAT3. (A) H1299 cells were
transfected with siNIPBL or non-targeting scramble siRNA for 48 h, RT-PCR analysis of STAT3, c-Myc, and Mcl-1 mRNA levels. * P <0.05. (B) After
transfection 72 h, H1299 cells collected and subjected to western blot analysis for detection of NIPBL, STAT3-related proteins and apoptosis-associated
proteins levels, a-tubulin was used as a loading control. Shown were representative blots of three independent experiments. (C) Chromatin-
immunoprecipitation (ChIP) assays were used to demonstrate that NIPBL bind to STAT3 promoter region. Two pair of primer (STAT3-p1 and
STAT3-p2) was designed to amplify different fragments of STAT3 promoter region. Input DNA before immunoprecipitation was used as
positive control, as negative control, a nonspecific antibody (a-IgG) was used for precipitation.
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cers, and acts as a potent pro-survival and anti-apoptotic
signaling protein, these data demonstrated that NIPBL si-
lencing inhibited cell growth, possibly via downregulating
STAT3 and STAT3 target genes in NSCLC cells.
To further analyze the relationship between NIPBL
and STAT3, we performed ChIP assays, using anti-
NIPBL antibody, followed by PCR with the primers spe-
cific for the STAT3 promoter, as shown in Figure 5C.
We found that NIPBL bound to the STAT3 promoter re-
gion, which suggested that NIPBL might directly regu-
late the expression of STAT3 protein.
Discussion
In this study, we did a comprehensive analysis of a cohe-
sin loading factor, NIPBL, in NSCLC. The immunohisto-
chemical results demonstrated that increased NIPBLexpression was positively associated with tumor differen-
tiation and tumor metastasis, and that high NIPBL ex-
pression was associated with shorter overall and relapse
free survival in patients with lung adenocarcinoma, the
most common type of NSCLC. Our analyses provided
compelling evidence that NIPBL expression was a novel
prognostic marker in NSCLC, although further studies
using a larger independent patient set would be neces-
sary to confirm this observation. The data from cell lines
revealed that downregulation of NIPBL strongly corre-
lated with decreased cellular proliferation and viability,
impaired migration, impaired invasion ability, and en-
hanced proapoptotic effects in human NSCLC cells.
These findings supported the hypothesis that NIPBL
may play a positive role in the carcinogenesis of NSCLC.
Affected CdLS individuals were shown to have altered
developmental gene expression and development was
Xu et al. Journal of Translational Medicine  (2015) 13:153 Page 10 of 12reduced by approximately 30% NIPBL transcript levels,
but no obvious cohesin-dependent chromosome cohe-
sion defects were observed, suggesting that pathogenesis
of CdLS was more likely due to the dysregulation of nu-
merous developmental genes that resulted from muta-
tions in NIPBL [22]. A non-canonical role for NIPBL as
a key regulator of gene expression has been proposed
[5,23]. In different species, SCC2 has been shown to dir-
ectly facilitate expression of myc, a critical regulator of
cell proliferation and protein synthesis [17,22,24]. In
mouse embryonic stem cells, Nipbl could promote ex-
pression of genes required for pluripotency, such as,
Oct4 and Nanog [18]. Numerous proliferation and pluri-
potency associated genes could be upregulated by
NIPBL, suggesting that NIPBL participated in the cellu-
lar decision to proliferate or differentiate. NIPBL might
also act as an oncogene. Our results suggested the over-
expression of NIPBL in lung cancer with proliferative
potential and aberrant differentiation. These results sug-
gested that increased NIPBL contributed to cancer
progression.
Rare NIPBL mutations were also identified in lung car-
cinoma, breast carcinoma, and colorectal tumors [19],
but the pathological importance of these mutations in
cancer remains unknown. Additional evidence showed
that somatic mutations in the NIPBL gene were found in
gastric and colorectal cancers with high microsatellite
instability [25]. These results suggested the possibility
that underexpression of NIPBL was also associated with
carcinogenesis. Accurate and timely segregation of sister
chromatids in the cell cycle is essential for maintaining
genome integrity [26,27]. A possible explanation for un-
derexpression of NIPBL also associated with carcinogen-
esis was that insufficient NIPBL might interfere with its
interaction with the cohesin complex, which leads to
genome instability by disturbing the segregation and co-
hesion of sister chromatids, thus contributing to aneu-
ploidy in carcinogenesis. Therefore, we hypothesized
that NIPBL might act as a gatekeeper of cell fate, main-
taining the balance and modulation of critical cellular
processes through its multiple roles. The adverse out-
comes of varying the expression of NIPBL could be due
to the different roles of NIPBL in cellular regulation.
Both cisplatin-based and paclitaxel-based chemother-
apies are first-line treatments in NSCLC, Gemcitabine
hydrochloride is also used in combination with other
chemotherapy drugs to treat NSCLC, but their use has
been limited by drug resistance. In this study, we found
that decreased NIPBL increased apoptosis induced by
these chemotherapeutic drugs, and this correlated with
the levels of NIPBL expression. The pharmacological ac-
tivities of these chemotherapeutic drugs are totally dif-
ferent, but their final mechanism of action is activation
of apoptosis in cancer cells. It was known that cancercells developed resistance to cytotoxic agents and this
was related to resistance to apoptosis [28]. Therefore,
our results supported the concept that NIPBL acted as
an apoptosis inhibitor, thus promoting chemotherapeutic
drugs resistance. Suppression of NIPBL expression could
therefore enhance the cytotoxicity of chemotherapeutic
drugs.
By measuring the mRNA and protein levels of compo-
nents of the cohesin complex in NIPBL knockdown
H1299 cell lines, we noted that cohesin core compo-
nents RAD21 and SMC1A showed similar downregula-
tion that was directly correlated with the level of NIPBL
expression (data not shown). Interestingly, altered RAD21
or SMC1A expression was also reported as associated
with distinct cancer phenotypes [29-32], although the
complete mechanism of cohesin biology remains to be de-
termined. Cohesin core components and their regulatory
proteins could function together, or separate cohesin sub-
units could play different roles in different physiological
and pathological contexts. It will be interesting to study
how a single protein complex can be involved in so many
cellular processes.
Knowledge of how NIPBL regulates molecular path-
ways is relatively limited. To investigate whether down-
regulation of NIPBL leads to alterations in transcription,
we performed RNA-seq assays after knockdown of
NIPBL protein in H1299 cells (data not show). We con-
firmed that insufficient NIPBL was associated with sig-
nificant decrease in mRNA and protein expression of
STAT3 and its target factors c-Myc, Mcl-1, and Bcl-2.
STAT3 is a component of the signal transducers and ac-
tivators of the transcription (STATs) family, which acts
as an important transcription factor, and plays a role in
normal development and cancer progression by regulat-
ing cell survival, proliferation, and apoptosis [33,34].
STAT3 was frequently constitutively activated in many
human cancers, and STAT3 activation was also associ-
ated with therapeutic drug resistance [35]. Tumorigenic
STAT3 is likely due to the aberrant activity of STAT3’s
upstream signaling pathways, such as, JAK2, EGFR, Src
and HER2 [36]. C-Myc protein is a key regulator in cell
growth and proliferation [37,38], and Mcl-1 protein be-
longs to the Bcl-2 family which maintains cell survival
by inhibiting cell apoptosis [39]. Overexpression of both
proteins enhanced many cancer types [38,40,41]. In this
study, we showed that NIPBL could directly bind to the
promoter region of the STAT3 gene, suggesting that
NIPBL might act as an upstream regulator of STAT3. It
is hypothesized that downregulation of NIPBL could in-
hibit the activation of STAT3, reduce the expression of
known STAT3 downstream genes, and contribute to the
inhibition of cell growth, migration, invasion, and the in-
duction of apoptosis. In addition, from flies to humans,
it is remarkable that positive regulation of c-Myc
Xu et al. Journal of Translational Medicine  (2015) 13:153 Page 11 of 12transcription by Nipped-B/Nipbl/NIPBL is directly and
evolutionarily conserved [14,24,42].
Base on previously reports, NIPBL may be involved in
gene regulation through various mechanisms. In differ-
ent model organisms, genome-wide mapping identified
extensive colocalization between cohesin and CCCTC-
binding factor (CTCF functions as a transcriptional insula-
tor) [8,43-45], but in mouse embryonic stem cells, Nipbl,
cohesin and mediator (transcriptional co-activator) colo-
calized at many sites other than CTCF binding sites [18].
These results suggested that cohesin or Nipped-B/Nipbl
regulate gene expression might occur via both CTCF-
dependent and CTCF-independent pathways. Recently,
NIPBL ChIP analyses have identified high affinity NIPBL
binding sites in different cell lines which did not overlap
with cohesin binding sites, but overlapped almost exclu-
sively with the promoters of active genes. These results
suggested a cohesin-independent role for NIPBL in tran-
scriptional regulation [15]. NIPBL may be involved in gene
regulation through various mechanisms in various cell
types. Therefore, it will be interesting to elucidate the
mechanisms by which NIPBL both negatively and posi-
tively regulates the transcription of certain genes in
NSCLC.
Conclusions
In summary, to our knowledge this study was the first to
show that NIPBL expression levels could predict the
clinical outcome and the resistance to chemotherapy in
NSCLC. NIPBL inhibition had in vitro effects on prolif-
eration, invasion, and apoptosis control. In the future,
precise molecular details of regulation remain to be fur-
ther studied, and targeting NIPBL might provide a novel
therapy for NSCLC.
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